Envestnet Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$146M Buy
3,959,430
+1,185,996
+43% +$56.2M 0.04% 413
2025
Q4
$141M Sell
2,773,434
-1,150,167
-29% -$58.8M 0.04% 397
2025
Q3
$218M Sell
3,923,601
-262,089
-6% -$15.3M 0.06% 288
2025
Q2
$289M Sell
4,185,690
-305,824
-7% -$20.8M 0.08% 217
2025
Q1
$312M Buy
4,491,514
+323,831
+8% +$26.7M 0.1% 186
2024
Q4
$359M Sell
4,167,683
-110,977
-3% -$12M 0.12% 157
2024
Q3
$509M Buy
4,278,660
+24,480
+0.6% +$3.26M 0.16% 108
2024
Q2
$607M Buy
4,254,180
+58,935
+1% +$7.81M 0.21% 86
2024
Q1
$539M Sell
4,195,245
-18,733
-0.4% -$2.23M 0.2% 86
2023
Q4
$436M Sell
4,213,978
-338,503
-7% -$33.5M 0.18% 107
2023
Q3
$414M Buy
4,552,481
+1,007,251
+28% +$88.7M 0.19% 101
2023
Q2
$287M Sell
3,545,230
-7,072,502
-67% -$578M 0.13% 135
2023
Q1
$271M Buy
10,617,732
+7,074,496
+200% +$502M 0.13% 131
2022
Q4
$240M Sell
3,543,236
-65,696
-2% -$3.85M 0.12% 151
2022
Q3
$180M Sell
3,608,932
-6,330
-0.2% -$339K 0.1% 181
2022
Q2
$201M Buy
3,615,262
+407,996
+13% +$22.6M 0.11% 169
2022
Q1
$178M Buy
3,207,266
+372,244
+13% +$19.1M 0.09% 201
2021
Q4
$159M Buy
2,835,022
+151,076
+6% +$8.18M 0.08% 226
2021
Q3
$129M Buy
2,683,946
+84,280
+3% +$4.07M 0.07% 235
2021
Q2
$109M Buy
2,599,666
+101,754
+4% +$3.94M 0.06% 253
2021
Q1
$84.2M Buy
2,497,912
+153,532
+7% +$5.47M 0.05% 282
2020
Q4
$81.9M Buy
2,344,380
+30,556
+1% +$1.06M 0.06% 238
2020
Q3
$80.3M Sell
2,313,824
-17,250
-0.7% -$575K 0.07% 213
2020
Q2
$76.3M Buy
2,331,074
+77,512
+3% +$2.47M 0.07% 212
2020
Q1
$67.8M Buy
2,253,562
+150,230
+7% +$4.47M 0.08% 191
2019
Q4
$60.9M Buy
2,103,332
+53,444
+3% +$1.48M 0.06% 235
2019
Q3
$53M Buy
2,049,888
+79,220
+4% +$2M 0.06% 252
2019
Q2
$50.3M Buy
1,970,668
+45,900
+2% +$1.13M 0.06% 229
2019
Q1
$50.3M Sell
1,924,768
-59,782
-3% -$1.47M 0.07% 209
2018
Q4
$45.7M Buy
1,984,550
+815,682
+70% +$18.1M 0.07% 197
2018
Q3
$27.6M Sell
1,168,868
-81,830
-7% -$2M 0.05% 143
2018
Q2
$28.8M Buy
1,250,698
+1,130,790
+943% +$26.9M 0.07% 137
2018
Q1
$2.94M Sell
119,908
-2,173,202
-95% -$57.1M 0.01% 566
2017
Q4
$61.5M Buy
2,293,110
+16,572
+0.7% +$421K 0.14% 88
2017
Q3
$54.8M Sell
2,276,538
-59,384
-3% -$1.34M 0.13% 88
2017
Q2
$50.1M Buy
2,335,922
+479,380
+26% +$9.67M 0.14% 96
2017
Q1
$31.8M Buy
1,856,542
+450,922
+32% +$7.85M 0.1% 133
2016
Q4
$25.2M Buy
1,405,620
+222,386
+19% +$4.03M 0.09% 162
2016
Q3
$24.6M Sell
1,183,234
-207,066
-15% -$5.13M 0.1% 159
2016
Q2
$37.4M Buy
1,390,300
+83,396
+6% +$2.29M 0.15% 120
2016
Q1
$35.4M Sell
1,306,904
-76,384
-6% -$2.05M 0.15% 114
2015
Q4
$40.2M Sell
1,383,288
-45,850
-3% -$1.27M 0.18% 101
2015
Q3
$38.8M Sell
1,429,138
-11,078
-0.8% -$314K 0.19% 98
2015
Q2
$39.4M Buy
1,440,216
+64,480
+5% +$1.81M 0.19% 110
2015
Q1
$36.7M Buy
1,375,736
+1,316,582
+2,226% +$30.3M 0.19% 113
2014
Q4
$1.25M Sell
59,154
-4,520
-7% -$101K 0.01% 483
2014
Q3
$1.52M Buy
63,674
+4,096
+7% +$94.3K 0.02% 474
2014
Q2
$1.38M Buy
59,578
+17,908
+43% +$395K 0.01% 453
2014
Q1
$951K Sell
41,670
-34,340
-45% -$732K 0.01% 476
2013
Q4
$1.4M Buy
76,010
+4,810
+7% +$83.8K 0.02% 365
2013
Q3
$1.21M Sell
71,200
-480
-0.7% -$8.07K 0.01% 370
2013
Q2
$1.11M Buy
+71,680
New +$1.19M 0.01% 389

Other funds holding NVO

Envestnet Asset Management's NVO Position: Q1 2026 in Review

Envestnet Asset Management increased its Novo Nordisk (NVO) stake by 43% in Q1 2026, buying an estimated $56.2M and bringing the position to 3,959,430 shares worth $146M. The position accounts for 0.04% of the portfolio, ranked #413.

Envestnet Asset Management first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $607M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Envestnet Asset Management held 3,959,430 shares of Novo Nordisk worth $146M as of Q1 2026.
  • Envestnet Asset Management bought 1,185,996 Novo Nordisk shares in Q1 2026, an estimated $56.2M.
  • Novo Nordisk made up 0.04% of Envestnet Asset Management's portfolio in Q1 2026, its #413 holding.
  • Envestnet Asset Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Envestnet Asset Management's Novo Nordisk position peaked at $607M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.